These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35300912)
61. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997 [TBL] [Abstract][Full Text] [Related]
62. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326 [TBL] [Abstract][Full Text] [Related]
63. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting? Berkovic MC; Bilic-Curcic I; Bozek T; Mahecic DH; Majanovic SK; Canecki-Varzic S; Andric J; Marusic S; Mrzljak A World J Diabetes; 2020 Nov; 11(11):540-552. PubMed ID: 33269065 [TBL] [Abstract][Full Text] [Related]
64. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. Hsiao FC; Yen KC; Chao TF; Chen SW; Chan YH; Chu PH J Clin Endocrinol Metab; 2022 Aug; 107(9):2493-2499. PubMed ID: 35776065 [TBL] [Abstract][Full Text] [Related]
66. Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone? Sawami K; Tanaka A; Node K Hypertens Res; 2023 Aug; 46(8):1892-1899. PubMed ID: 37258623 [TBL] [Abstract][Full Text] [Related]
67. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Varshney N; Billups SJ; Saseen JJ; Fixen CW Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754 [TBL] [Abstract][Full Text] [Related]
68. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States. Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL Kidney Med; 2023 Jan; 5(1):100564. PubMed ID: 36593878 [TBL] [Abstract][Full Text] [Related]
70. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents. Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC; Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906 [TBL] [Abstract][Full Text] [Related]
71. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G). Ohsugi M; Eguchi K; Thietje Mortensen J; Yamamoto Y; Ueki K Diabetes Res Clin Pract; 2023 Sep; 203():110841. PubMed ID: 37481115 [TBL] [Abstract][Full Text] [Related]
72. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. DeFronzo RA Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726 [TBL] [Abstract][Full Text] [Related]
73. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430 [TBL] [Abstract][Full Text] [Related]
74. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020. Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049 [TBL] [Abstract][Full Text] [Related]
75. Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease. Aminian A; Gasoyan H; Zajichek A; Alavi MH; Casacchia NJ; Wilson R; Feng X; Corcelles R; Brethauer SA; Schauer PR; Kroh M; Rosenthal RJ; Taliercio JJ; Poggio ED; Nissen SE; Rothberg MB Ann Surg; 2024 Sep; 280(3):414-423. PubMed ID: 38860374 [TBL] [Abstract][Full Text] [Related]
76. Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes. Frieling K; Monte SV; Jacobs D; Albanese NP J Am Pharm Assoc (2003); 2021; 61(6):772-777. PubMed ID: 34266747 [TBL] [Abstract][Full Text] [Related]
77. Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure. Wolff Sagy Y; Lavie G; Ramot N; Battat E; Arbel R; Reges O; Dicker D Nat Med; 2024 Aug; 30(8):2337-2342. PubMed ID: 38749475 [TBL] [Abstract][Full Text] [Related]
78. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648 [TBL] [Abstract][Full Text] [Related]
79. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP Eur J Prev Cardiol; 2021 Mar; 28(1):22-29. PubMed ID: 33624059 [TBL] [Abstract][Full Text] [Related]
80. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Desai A; Petrov J; Hashash JG; Patel H; Brahmbhatt B; Kochhar GS; Farraye FA Aliment Pharmacol Ther; 2024 Sep; 60(5):620-632. PubMed ID: 38938071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]